Concurrently in 2021, Himeda et al. extended their 2016 usage of dCas9 by fusing it to epigenetic regulators to achieve stable repression of DUX4 expression with minimal off-target effects observed in FSHD myocytes, demonstrating its potential as a viable therapeutic option [46]. This evidence concerns the gene DUX4 and Facioscapulohumeral dystrophy.